University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Mechanical (and Materials) Engineering -Dissertations, Theses, and Student Research

Mechanical & Materials Engineering,
Department of

Spring 5-7-2021

DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC ORAL
BIOLOGIC DRUG DELIVERY
Benjamin Wankum
University of Nebraska-Lincoln, bwankum2@unl.edu

Follow this and additional works at: https://digitalcommons.unl.edu/mechengdiss
Part of the Materials Science and Engineering Commons, and the Mechanical Engineering Commons

Wankum, Benjamin, "DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC ORAL BIOLOGIC DRUG
DELIVERY" (2021). Mechanical (and Materials) Engineering -- Dissertations, Theses, and Student
Research. 166.
https://digitalcommons.unl.edu/mechengdiss/166

This Article is brought to you for free and open access by the Mechanical & Materials Engineering, Department of
at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Mechanical (and
Materials) Engineering -- Dissertations, Theses, and Student Research by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC ORAL BIOLOGIC DRUG
DELIVERY
By
Benjamin Paul Wankum

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Mechanical Engineering and Applied Mechanics

Under the Supervision of Professor Benjamin S. Terry

Lincoln, Nebraska

May, 2021

DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC BIOLOGIC DRUG
DELIVERY
Benjamin Paul Wankum, M.S.
University of Nebraska, 2021
Advisor: Benjamin Terry
A biologic drug is a drug that is produced by a living organism. Biologic drugs
are used to treat various medical conditions such as arthritis, diabetes, or certain forms of
cancers due to their high potency and high selectivity of action. Drawbacks of biologics
include their poor stability in the gastrointestinal tract and their poor absorption. In effect,
this gives the drugs very low bioavailability and short therapeutic half-lives. To combat
these obstacles, current delivery methods include subcutaneous injections at home or
intravenous or intramuscular injections in a medical facility.
The overall scientific goal of the research was to utilize subcutaneous needle
injection methodology used for parenteral systemic biologic drug delivery to solve the
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or
cancers. Previous prototype tissue attachment mechanism (TAM) systems have shown
tissue attachment in vivo, without the delivery of a drug. The methodology of this study
was to use the same successful device but integrate an osmotic pump and a hypodermic
needle to deliver a drug after attachment to the intestine. The delivery of the drug was
deemed successful based on the drug's concentration in blood samples.
The integrated TAM and drug delivery needle were designed, tested, and
integrated on the benchtop until consistent successful drug delivery results were obtained.
Once the device reliably delivered drug on excised tissue, it was tested in vivo on six

swine for systemic drug delivery. The first study had shorter than expected TAM
attachment times causing minimal drug to be delivered, but the methodology of the study
was learned. After improving the device and study setup, a second in vivo study was
performed on another six swine. The study showed much stronger evidence of drug
delivery. Both positive controls and one of the three experimental groups showed
systemic drug delivery. Both studies were a methods development study, so the number
of pigs in the results did not meet the power for statistical significance.
Also, in this work, a theoretical osmotic pump was designed to be integrated with
the TAM and full capsule. Although not actually fabricated, the osmotic pump would be
fabricated using the same material and ratio of drug to total volume as a commercial
osmotic pump. The commercial osmotic pump was tested in a swine small intestine and
showed proof of drug delivery.
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Chapter 1: Introduction
1.1

Biological Drugs
A biological drug (biologic) is a drug that is derived from any living organism

such as humans, animals, or microorganisms [1]–[3]. Compared with conventional
synthetic chemical drugs, biologics are relatively large and complex molecules [4]–[6].
They are made up of proteins, carbohydrates, nucleic acids, or a complex composite of
these substances [1], [7], [8]. Biological drugs are used to treat various medical
conditions such as rheumatoid arthritis, diabetes, or forms of cancers due to their high
potency and high selectivity of action [2], [9]–[11]. Some of the most common biological
drugs in the United States include adalimumab (Humira®) or rituximab (Rituxan ®) for
rheumatoid arthritis, semaglutide (Ozempic®) or dulaglutide (Trulicity®) for treatment
of diabetes, or trastuzumab (Herceptin®) for the treatment of breast cancer [9], [12]–[17].
Although these drugs are effective, they must cross numerous obstacles before reaching
the pathological site [18]. Specifically, biologics are poorly absorbed in the
gastrointestinal (GI) tract because of their physio-chemical properties including size,
charge, and hydrophilicity [19]–[22]. Frequently, an orally administered biologic may
become inactive or less potent as it might be hydrolyzed or degraded enzymatically
before reaching its targeted location [18], [23], [24]. After being degraded, it is excreted
rapidly through the urinary system, leaving a minimal amount of drug at the targeted site
[25]. Some biologics can be administered via a mucosal route, such as parathyroid
hormone [26]. Non-protein biologics (such as steroid hormones) can be administered
orally [27]. However, many biological therapeutics typically require parenteral delivery
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which includes intravenous (IV) or intramuscular (IM) delivery in hospitals or
subcutaneous (SC) injections at the patient’s home (e.g. via insulin pen) [28], [29].
Unfortunately, IV, IM, and SC administrations can be painful or psychologically
daunting causing many people to fear hypodermic needle placements and potentially drop
out of their treatment [30]. It is estimated that 10% of the United States’ population has
trypanophobia or needle phobia [31]. In a study performed on 12,582 people who were
given the option of a free influenza vaccine via intranasal or SC injection, only 1,600
people chose to be vaccinated. Of the 1,600 subjects, 97% of the people selected the nasal
route. The subjects were asked the reason for choosing the nasal spray, and 14%
responded with fear of injection [32].
Aside from the fear of needles, injections are more challenging to use in a long-acting
continuous drug input system outside of the hospital since the patients cannot
continuously treat themselves [33]. When investigating new drug delivery methods,
pharmacokinetics (PK) and pharmacodynamics (PD) are used to compare delivery
methods [34]. Pharmacokinetics is the study and mathematical description of the
relationship between the dose of a drug and its concentration in body fluids and tissues
over time [35]. Pharmacodynamics, on the other hand, is the quantitative study of the
relationship between drug exposure and pharmacologic or toxicologic responses [36].
Simply, PK represents “what the body does to the drug” and PD represents “what the
drug does to the body”, specifically the targeted site, tissue, organ, etc. [37]. One of the
most important pharmacokinetic parameters is bioavailability (F), which is the fraction or
percent of an administered drug that reaches systemic circulation [38]. Many times,
absolute bioavailability is used to compare different methods of drug delivery (i.e. oral
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administration) to an IV injection [39]. Equation (1) shows the formula used to calculate
bioavailability.

𝐹=

𝐴𝑈𝐶𝑥
𝐴𝑈𝐶𝐼𝑉

∗

𝐷𝑥
𝐷𝐼𝑉

(1)

Where the subscripts x and IV denote the delivery method of interest and intravenous
delivery, respectively. Next, AUC means the area under the curve, which represents the
area under the plasma concentration curve [40]. The area is defined by the plasma drug
concentration on the y-axis and time on the x-axis. Figure 1 shows a generic example of
an AUC comparing an oral administration to an IV administration. Lastly, D is the
dosage of the drug administered, but many times dosages are the same between delivery
methods, so it can be removed from the equation.

Figure 1. An example graph showing the area under the curve (AUC) of an oral dose and
an IV dose [41].
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Controlled drug delivery aims to deliver drugs to the target sites at desired rates and
times, thus enhancing the drug efficacy, pharmacokinetics, and bioavailability while
maintaining minimal side effects [42], [43]. To achieve a controlled drug delivery, many
approaches are being explored, such as chemically modifying the biologic, encapsulating
or protecting the drug, applying external transdermal microneedle patches, and more
recently, novel oral drug delivery devices [44]–[47]. Ingestible drug delivery devices
present possibilities for systemic delivery of biological drugs with or without chemical
alteration [48], [49]. These easily ingestible devices can carry small electronics,
mechanical components, mucoadhesive patches, or dissolvable microneedles which can
deliver drug along the GI tract [50]–[53].

1.2

Oral Drug Delivery Devices
In 2002, Eiamtrakarn et al. developed a gastrointestinal mucoadhesive patch system

(GI-MAPS) to overcome the challenges associated with conventional drug delivery

(Figure 2.) [54]. The patch system consisted of four layers: (I.) a backing layer made of a
water-insoluble polymer to protect biological drugs from enzymatic hydrolysis, (II.) a
surface layer made of a polymer sensitive to intestinal pH, (III.) a drug-carrying middle
layer, and (IV.) an adhesive layer between the middle and surface layers to create a high
concentration gradient between the patch and intestinal enterocytes. In this study, three
different surface layer polymers were tested, hydroxypropyl methylcellulose phthalate
(HP-55), Eudragit L100, and Eudragit S100. Each device was tested in three fasted
beagle dogs using fluorescein as a model drug to track Tmax, (the time when plasma
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concentration reaches its maximum level). Each surface polymer tested with the device
demonstrated that the targeting of the device was obtained. In another trial, each device
was loaded with 125 μg of recombinant human granulocyte colony-stimulating factor (GCSF) to detect an increase in total white blood counts. Each device was administered
orally to four dogs and 125 μg of G-CSF was delivered intravenously to three dogs for
comparison. In comparison to the IV injection, the total increase of white blood cells
indicated the bioavailability of G-CSF was 23%, 5.5%, and 6.0% for Eudragit L100, HP55, and Eudragit S100 systems, respectively [55]. The bioavailability of the device was
the highest value achieved compared with other oral drug delivery systems at the time
[54].

Figure 2. GI-MAPS oral device comprising mucoadhesive patches and an enterically
coated capsule [54].
A group from MIT developed an oral biological delivery system (Figure 3) inspired
by a leopard tortoise’s ability to passively reorient [56]. The self-orienting millimeterscale applicator (SOMA) autonomously positions itself to interact with GI tissue. The
device is designed as a monostatic body, meaning it only has one stable position. This is
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accomplished by a shifted center of mass and a high-curvature upper shell that enables
self-orientation to the preferred upright position. After correctly orienting itself, the
device deploys a microneedle array manufactured from active pharmaceutical ingredients
directly through the gastric mucosa while avoiding perforation. By using insulin as the
model drug, SOMA was tested in rats and swine to demonstrate safety and efficacy. The
study showed that the plasma insulin levels from SOMA were comparable to those with
subcutaneous admission [56].

Figure 3. SOMA self-orienting to its stable position and delivering drug [56].
The same MIT group developed another biological drug delivery device termed
the luminal unfolding microneedle injector (LUMI) pill (Figure 4) [53]. LUMI consists of
three degradable arms spring-loaded into a capsule. Each arm consists of a dissolvable
drug-loaded microneedle patch. The device utilizes a polymer coating, designed to
dissolve at a pH greater than 5.5, in combination with a polyethylene glycol (PEG)
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coating to encapsulate a compressed spring that propels the LUMI out of the capsule.
After the device is propelled from the capsule, each arm stretches the tissue and presses
the microneedle patches into the tissue wall, where they penetrate the epithelial barrier,
dissolve and release the encapsulated drug [57]. The researchers used insulin as a model
drug and demonstrated that LUMI provided a faster pharmacokinetic uptake profile and a
systemic uptake greater than 10% of that of a subcutaneous injection over a 4-h sampling
period [53].

Figure 4. The luminal unfolding microneedle injector (LUMI) actuation scheme [53].
Rani Therapeutics is a private-based company that is developing an ingestible
drug delivery system named the RaniPill (Figure 5). From the outside, the Rani Pill
appears to be a standard capsule, but several mechanisms occur after ingesting. After
entering the GI tract, the outer capsule dissolves exposing a tiny valve that separates two
chambers filled with citric acid and bicarbonate. Then the valve dissolves causing the two
chemicals to combine which produces carbon dioxide. The carbon dioxide gas inflates a
balloon-like structure which drives dissolvable sugar microneedles into the wall of the
intestine. The needles then detach from the remaining capsule and slowly dissolve,
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introducing the drug into nearby blood vessels. The remaining components either
dissolve or pass through the body [58]. Rani Therapeutics is currently testing daily oral
insulin pills in human trials [59].

Figure 5. The RaniPill actuation process [59].

1.3

Previous Research and Approach
Although there have been several semi-successful oral biological drug delivery

devices produced by multiple groups, they each lack the ability for long-term attachment
(greater than 2 weeks). Terry et al had previously been developing a long-term ingestible
capsule robot (ICR) for the use of active diagnostics, intervention, and bio-sensing
(Figure 6) [60]. They designed this with the intention that if physicians can constantly
monitor specific elements of the GI tract, better clinical diagnostics could be achieved.
For example, the temperature and pH of the intestine have been considered two vital
factors that control enzyme activity which thereby affect digestive function [61]. In
addition to diagnostics, a long-term attachment may provide other possible functions such
as physical tissue manipulation or drug delivery.
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Figure 6. Schematic showing the noninvasive implantation of attachment mechanism on
the mucosal lining of the GI tract via a long-term ingestible capsule robot (ICR).
Employing the same design, our current group wanted to use the ICR for systemic
delivery of physically and chemically unaltered biological drugs into the submucosa layer
of the small intestine. The use of existing, unmodified biological drugs eliminates the
cost and complications associated with developing new drugs. It is estimated that new
drug development can cost somewhere between $500 million to $2 billion [62], meaning
delivery of unaltered biological drugs could save industries money and time. Despite
having the capability for systemic drug delivery, the previous ICR had some drawbacks.
The dimensions of that ICR were not within the standard ingestible capsule range and
contained several electronic components unnecessary for drug delivery. The fabrication
process was complicated therefore the device was not mass-producible. Furthermore, all
previous optimizations were done on dead, excised porcine intestinal tissue lacking the
dynamic properties of live tissue. In this current work, the TRL is developing a mass-
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producible, standard capsule sized ICR tailored for long-term drug delivery. The drug
delivery ICR is designed so that it passively travels to the small intestine via digestive
peristalsis after it is swallowed. The goal is for the ICR to deploy the drug-carrying
payload into the submucosa via a novel tissue attachment mechanism referred to as the
"TAM".
Inspired by intestinal parasites, the system relies on suction or negative pressure
for tissue attachment. Biomimicking the sucking action of a parasite, the TAM consists of
an orifice with stainless steel needles angled down and inward, acting as the teeth of a
parasite, referred to as the TAM needles (Figure 7A). The stainless steel orifice and
needles are mounted on a 3D printed TAM body via ultraviolet (UV) glue. (Figure 7B).
Upon reaching the small intestine, the TAM is ejected from the ICR and remains adhered
to the mucosa for a prolonged period while maintaining intimate contact with the tissue.
An advantage of using the TAM for long-term attachment is the lack of pain receptors
along the GI tract [63]. One possible application enabled by this extended intimate
contact with tissue is extended-release drug delivery. The payload could be contained
inside the TAM unaltered and separate from the ICR, thus enabling the payload to be
simple, small, and biocompatible. Like a subcutaneous injection, the drug may be
injected directly through the submucosa layer, thus bypassing the barrier function of the
small intestine wall.
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Figure 7. A) TAM orifice and TAM needles. B) TAM Body
To maximize attachment reliability, my collaborator Sunandita Saker, designed
and optimized a mass-producible miniaturized TAM suited for a drug delivery ICR.
Based on previous research, attachment success and duration depends on multiple
independent factors related to TAM geometry (orifice diameter, number of needles,
needle angle, needle length, needle width), vacuum volume, and small intestine tissue
location (duodenum, jejunum, or ileum) [60]. Sunandita implemented a factorial design
of experiments in her research to screen and optimize the design with a reduced number
of trials for optimal success. Concurrently, the drug delivery portion of the ICR was
developed and is the main topic of this thesis. Due to the simultaneous development of
the optimized TAM geometry, throughout this work the dimensions of the TAM change.
Also, the ICR used in this research does not contain any electronics or robotic functions,
therefore it will be referred to as the capsule.
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1.4

Research Objectives
The overall scientific objective of the research was to utilize subcutaneous needle

injection methodology used for parenteral systemic biologic drug delivery to solve the
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or
cancers. This was accomplished by showing proof-of-feasibility of biological drug
delivery via needle injection into the small intestine. The first goal was to develop a
prototype TAM that integrated a commercial off-the-shelf (COTS) drug delivery system
for systemic administration of glucagon-like peptide 1 (GLP-1) or a suitable surrogate via
the intestinal wall. Specifically, a custom needle was developed for administering drug to
the submucosa of the small intestine. A COTS osmotic pump was then integrated with
the custom needle and tested for its drug delivery performance using benchtop models.
The injection needle and the COTS pump were incorporated into the TAM, and the entire
system was tested in a live porcine model for long-term drug delivery using adalimumab
as the administered biological drug.
The second goal was to design (without physical implementation) a custom
osmotic pump that is compatible with the capsule system. A custom osmotic pump was
designed using dimensions and specifications from a commercial manufacturer of these
types of pumps. The custom pump design met the criteria for use in the complete capsule
system but was not fabricated or tested in this current work.
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Chapter 2: Drug Delivery System
2.1 Functional Requirements of Drug Delivery System
1. Location of Delivery
The drug shall be delivered to the small intestine, ideally near the ileum region. The
ileum region is where most GLP-1 is naturally secreted from enteroendocrine cells (L
cells). Systemic delivery shall be administered to the submucosa.
2. Duration of Administration
The drug injection needle and osmotic pump should deliver GLP-1 (or a suitable
surrogate) for 4-7 days at a minimum bioavailability of 10%.
3. Success Rate
Although this project was designed to assess feasibility, we created a design that targets a
success rate of greater than 90%, i.e. at least four days of sufficient drug is administered
in 9 out of 10 TAM trials in different animals (to be studied in future work).
4. Animal
The TAM shall function properly in a fed, watered, and awake pig without harming one
animal.
5. Component Materials and Properties
The drug injection needle and the osmotic pump will be made with non-toxic parts. The
osmotic pump used in experiments will be a commercially available osmotic pump.
6. MRI Compatibility
The osmotic pump and drug delivery needle shall be compatible with MRI.
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7. Cost
The cost of the capsule system should be less than $50 (based on 50,000 units/year).
8. Manufacturability
The system shall be manufacturable in a timely fashion on a scale of 100,000 units/year.
Note: this quantity is different from the cost quantity to make a conservative case in both
categories.

2.2 Initial design of the Drug Injection Needle
The purpose of this task was to design and fabricate a custom injection needle for
implementation on the TAM to administer a biological drug to the submucosa. The initial
approach was to modify a 30-gauge brain infusion needle (BIN) available from Alzet
(Figure 8). The cannula was a 3 mm long stainless steel tube with a 0.16 mm inner
diameter and 0.31 mm outer diameter (the cannula was not hypodermic). The cannula
was selected as a preliminary approach since it could easily be attached to the Alzet
osmotic pumps that would be used for drug delivery later in this work. The cannula is
attached to the osmotic pump via a thin, small, plastic tube referred to as a catheter in this
work. The infusion kit was modified by removing the pedestal to expose the low-profile
L-shaped steel tubing. The TAM and drug delivery needle required space in the capsule
for tissue suction. To accommodate the BIN, a special capsule for benchtop testing was
designed and 3D printed (Figure 9-11). The vacuum aspiration port was necessary to
create a negative pressure but in the final design, the negative pressure will be carried on
board. After the capsule was created, varying lengths of BINs were inserted through the
capsule hole and each BIN’s base was glued to the bottom of the capsule. The complete
assembly is shown in Figure 12-15.
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A preliminary experiment was set up to determine if the BIN could deliver a drug
into the submucosa of excised intestinal tissue. The goal of the experiment was to
determine a criterion that showed drug delivery into the intestinal tissue with a needle.
For the tests, drug injection needle lengths varied from 0.5 mm to 2.5 mm (the tip of the
canula was 4.5 mm to 2.5 mm away from the top of the TAM body, respectively). In the
experiment, intestinal tissue was placed over the orifice of the TAM and drug injection
needle. Next, the vacuum valve was opened exposing the tissue to 600 μL of -25 mmHg
air. The negative pressure causes the intestinal tissue to aspirate into the space of the
capsule. When tissue is aspirated into the capsule, the TAM needles penetrate the mucosa
layer causing a firm attachment to the intestinal wall. During the aspiration of the
intestinal tissue, the drug injection needle could also penetrate the submucosa. After a
strong aspiration and attachment, colored water (mimicking drug) was pushed through
the drug injection needle and potentially into the intestinal tissue by a syringe pump and
catheter. Approximately 2 mL were injected into the intestinal tissue so that one could
easily visualize delivery, fulfilling the goal of finding a criterion to confirm delivery. The
experimental setup is shown in Figure 16.
After the preliminary experiments with the BIN integrated with the device, it was
decided using a 30-gauge needle to penetrate the submucosa and deliver a drug bolus was
feasible (Figure 17 and Figure 18). This experimental setup was used later in this work
and the results are explained in more detail. Although the Alzet BIN showed benchtop
drug delivery, it proved difficult to modify due to size constraints, so it was decided to
make custom drug injection needles using a 30-gauge needle. Another downside to using
the BIN was its inconsistency in piercing the mucosa. This was likely due to the BIN
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being a non-hypodermic needle, so succeeding experiments were tested with a
hypodermic needle. Figure 19 shows the difference between a blunt canula and a beveled
hypodermic needle.

Figure 8. Schematic of the brain infusion kit from ALZET.

Figure 9. CAD design of a capsule compatible with the BIN.
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Figure 10. CAD design of a capsule compatible with the BIN (cross-section).

Figure 11. CAD design of a capsule compatible with the BIN (bottom-view).
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Figure 12. CAD assembly of a capsule with the BIN.

Figure 13. CAD assembly of a capsule with the BIN (cross-section).

Figure 14. Assembly of a capsule with the BIN.
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Figure 15. Assembly of a capsule with the BIN (bottom-view).

Figure 16. Aspiration system with TAM/drug delivery needle.
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Figure 17. A representative image of BIN delivering a "drug" bolus. Colored (green)
water was used in this benchtop study.

Figure 18. Several “drug” boluses showing successful drug delivery using the BIN
prototype.
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Figure 19. A) ALZET's blunt canula (needle) and B) a beveled hypodermic needle.

2.3

Alternative Designs for Drug Delivery
To achieve reliable drug delivery, alternative design concepts were brainstormed

(Figure 21). The previously described bench-top experiments helped determine feasibility
and gain knowledge of the newly introduced concepts. Designs 2-4 required the needle to
connect to the osmotic pump via a catheter (or some other channel). In the concepts
below, the designed osmotic pump is shaped like a torus and is explored later in Chapter
3. The five alternative designs for attachment are described below and variations of the
capsule are shown in Figure 20.
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Figure 20. Concept model of capsule illustrating a torus-shaped osmotic pump.
Design 1: Perpendicular Needle
In the perpendicular needle design, the drug injection needle is within the torusshaped osmotic pump. The injection needle is connected directly to the osmotic pump
with 2-4 ports. The needle perpendicularly pierces the tissue upon aspiration. This
design was similar to the benchtop test described above with the BIN.
Design 2: Spring-Loaded Needle Outside Capsule
In the spring-loaded needle design, the injection needle is offset from the orifice
of the TAM, therefore away from the aspirated tissue. The drug needle penetrates the
tissue via a pre-loaded spring during the attachment sequence. The advantage of this
design is that it mitigates the possible problem of reduced blood flow to aspirated
tissue because the needle is outside the aspiration zone.
Design 3: Dual-Purpose Needle
In the dual-purpose needle design, the injection needle replaces one of the TAM's
needles and thus has dual purposes: to perform tissue attachment as well as provide a
channel for the drug. This concept would require no extra injection needles.
Design 4: Spring-loaded Needle within Capsule
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In the spring-loaded needle within the capsule design, the injection needle is
within the capsule at some undetermined orientation. In this design, the needle
approaches horizontally. The injection needle is spring-loaded and independent of
tissue aspiration.
Design 5: Drug pool through TAM hole
In the drug pool design, the concept is to create a reservoir of drug between the
pump and the tissue. The drug is pumped out of the osmotic pump over time and
stored in a closed capsule to prevent leakage into the lumen. The drug then enters the
submucosa through the channels created by the TAM needles. With this concept,
there is no direct drug injection, therefore no need to rely on drug needle penetration
depth.
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1

2

3

4

5

Figure 21. Concept model of a 1) perpendicular drug injection needle, 2) spring-loaded
drug injection needle, 3) dual-purpose drug injection needle, 4) spring-loaded drug
injection needle within the capsule, 5) drug pool within the capsule
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2.4 Down Selection Process
To determine which approaches to drug delivery were better suited to the application,
the six team members scored each design in a Pugh Matrix. After several iterations of
scoring, the concept with the highest score was the “drug pool” concept. However, due to
the novelty of this concept, it was decided to not use this idea in initial testing but rather
use the second-highest scoring and third-highest scoring concepts, the dual-purpose
needle, and the perpendicular drug injection needle, respectively.
Below are the evaluation parameters and weights (Table 2 and Table 3) for the last
iteration of the Pugh Matrix. The perpendicular drug injection needle was the reference,
so it received “0” for every parameter. The devices were scored based on the following
scale:
+2: much better than the baseline.
+1: somewhat better than the baseline.
0: equal to the baseline.
-1: somewhat worse than the baseline.
-2: much worse than the baseline.
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Table 1. Drug delivery evaluation criteria matrix with weights

Evaluation Parameters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Development risk/complexity
Technical feasibility
Development time
Development expense (technologies employed, cost to
integrate)
Robustness of penetration
Reliability of tissue penetration
Risk of penetrating too far
Needle engagement robustness
Robustness of drug delivery
Bioavailability performance
Size profile
Size Profile
Cost
Part complexity, tolerances required
Labor (manual vs automation)
IP favorability
Dead volumes and/or material use efficiency
Manufacturability
Assembly complexity
Manufacturability, chemical and/or wet processes
Scalability
Durability
Reliability over shelf life
Sterilization materials compatibility and risks

Weight
(1,3,9)
9
9
3
9
9
9
9
9
3
3
1
1
9
3
9
9
9
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Table 2. Average score (n=6) of the different design concepts.
Attachment Concepts
Evaluation
Parameters

Weight (1,3,9)

Perpendicular
Needle

Spring-Loaded
Needle

Dual
Purpose Needle

Spring-Loaded
within Capsule

Drug Pool

1
2
3

9
9
3

0.0
0.0
0.0

-1.5
-1.3
-1.3

-1.0
-1.0
-1.3

-1.8
-1.3
-1.3

0.3
0.8
1.3

4
5
6

9
9
9

0.0
0.0
0.0

1.5
-0.3
0.5

1.2
1.2
1.3

0.2
0.5
0.2

-0.5
1.8
-1.2

7

9

0.0

1.2

0.0

0.3

-1.3

8

9

0.0

-0.3

0.5

-0.5

0.3

9
10
11
12

3
3
1
1

0.0
0.0
0.0
0.0

-1.8
-0.5
0.0
-0.7

0.5
-0.2
0.8
0.8

-1.7
-0.5
0.0
-0.8

1.3
0.5
0.5
-0.5

13
14
15

9
3
9

0.0
0.0
0.0

-1.8
-0.7
-0.5

0.2
-0.5
-0.5

-1.8
-0.8
-0.5

0.3
0.0
0.3

16
17

9
9
Total
Weighed Total

0.0
0.0
0.0
0.0

-0.7
-0.5
-8.8
-48.2

0.0
-0.2
1.8
12.2
Legend

-0.7
-0.2
-10.8
-64.8

0.0
0.7
4.8
24.5

much worse

worse

improved

much
improved

-2

neutral
-1

0

1

2
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2.5 Design
The dual-purpose needle (Figure 22. A, C, and E) and perpendicular needle (Figure
22 B, D, and F-H) TAMs were designed and created to be tested with intestinal tissue on
the benchtop. All drug injection needles used in the experiment were 30-gauge
hypodermic needles. The dual-purpose needle had the same dimensions as the TAM
needles at the time, as shown in Figure 22 A and C. The needle was 3 mm long at a 30degree angle relative to the top of the TAM. The perpendicular needle concept had two
different versions created, referred to as the non-flush perpendicular needle (Figure 22 F
and H) and the flush perpendicular needle (Figure 22 G). The flush perpendicular needle
design was designed to have a smaller profile after attachment. This design was
introduced after preliminary successes with the non-flush perpendicular needle. In either
design, the 30-gauge hypodermic needle is inserted through a 0.5 mm hole in the TAM,
bent towards the center of the TAM, and then bent again up towards the top of the TAM
orifice (Appendix B shows the full manufacturing process). For both versions, the
vertical length of the needle could be modified if needed. After ad-hoc benchtop testing,
each version performed best when the hypodermic needle was even with the top of the
TAM orifice. To be at the orifice’s height, the vertical length of the non-flush and flush
perpendicular needle was 5 mm and 2 mm, respectively.
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Figure 22. A) CAD design of dual-purpose needle TAM. B) CAD design of
perpendicular needle TAM. C) Cross-section CAD design of dual-purpose TAM.
D) Cross-section CAD design of perpendicular TAM. E) Top view of the dual-purpose
needle TAM. F) Side view of perpendicular needles TAMs. 1 mm needle on the left and
5 mm needle on the right. The heigh of the needles could be altered. G) Side view of
perpendicular needle flush to TAM. H) Top view of perpendicular needles TAMs.
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2.6 Benchtop Experiments
Following the creation of the devices, they were tested with intestinal tissue on the
benchtop. Each device was tested in the ileum and jejunum regions of the intestine. The
ileum was selected for several reasons, its nutrient absorbent properties, thick wall layer,
and is the longest section of the human small intestine [64], [65]. The thicker the tissue is,
the easier it is to penetrate without perforating completely through the intestinal wall. The
jejunum was also used to see how the devices would perforate the thin wall of the
jejunum. The duodenum was excluded from the test because it had a similar thickness to
the ileum but less nutrient absorbing properties. The setup and attachment sequence was
the same as described earlier, Figure 16. However, with this setup, the TAM and drug
injection needle could be removed from the aspiration system. This was a major
advantage over the BIN assembly, creating a smaller attachment profile. After manually
injecting the sham drug (colored water) through the drug delivery needle via a syringe,
one of three results occurred: 1- The drug injection needle penetration was insufficient
and did not deliver the sham drug (Figure 23); 2- The drug injection needle sufficiently
penetrated (Figure 24) and formed a bolus of colored water within the intestinal tissue
(Figure 25). Occasionally when the bolus was delivered, colored water was visible
around the capillaries (Figure 25 and Figure 26); 3- The drug injection needle penetrated
too far and perforated the tissue. Each device type was tested 10 times at the jejunum and
ileum and recorded as a successful or unsuccessful delivery (Table 3). After running the
test, the flush perpendicular needle performed the best at the ileum, followed by the other
perpendicular device at the ileum. The dual-purpose device did not perform well at either
location. Each failed perpendicular device drug delivery at the jejunum occurred because
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the needle perforated too far. All other failures occurred because the needle did not
penetrate enough.
Table 3. Results of Benchtop Study.
Needle Type

Tissue Location

Flush Perpendicular
Non-Flush Perpendicular
Dual Purpose
Flush Perpendicular
Non-Flush Perpendicular
Dual Purpose

Ileum
Ileum
Ileum
Jejunum
Jejunum
Jejunum

Number of Successful
Reason for Failures
Deliveries (10 Trials)
10
7
3
6
5
3

Figure 23. Attached dual-purpose needle.

N/A
Penetration Short
Penetration Short
Full Perforation
Full Perforation
Penetration Short
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Figure 24. Perpendicular needle delivering drug.

Figure 25. Colored water is shown in/around vessels of the small intestine after delivery
from the perpendicular drug injection needle.
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Figure 26. Several boluses of colored water were delivered into the small intestine from
the perpendicular needle.

2.7 In vivo Experiment 1
2.7.1

Introduction
Based on the benchtop results, an in vivo experiment was designed. The flush

perpendicular drug delivery needle (referred to simply as the perpendicular needle
hereafter) was used in the ileum region. Adalimumab (PGN-001) was selected to be
delivered based on the guidance of our sponsor, Progenity. Adalimumab is a biological
drug used to treat arthritis and is detected in the blood at small concentrations: however,
it is nonabsorbable in the small intestine, making it an appropriate surrogate drug to GLP-
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1. Essentially, adalimumab is only detected in plasma samples if it is injected into the
submucosa. It does not show up on plasma samples if it is simply injected into the lumen
of the intestine.
2.7.2

Objectives

1) Penetrate small intestinal tissue with the drug injection needle without
gastrointestinal perforation
2) Deliver drug systemically via the submucosa of the small intestine for at least four
days.
2.7.3

Hypothesis

The drug delivery capsule will deliver non-absorbent biologics into the submucosa of
the small intestine and systemically thereafter. This was a methods development study, so
the number of pigs outlined in the procedure did not meet the power for statistical
significance.
2.7.4

Materials and Methods

After selecting the perpendicular drug delivery needle as the method to deliver the
drug, the design of the needle was slightly altered so that it had a smaller profile. This
design was tested and confirmed with benchtop testing. The final TAM/drug delivery
needle is shown in Figure 27. The capsule chamber was used to aspirate tissue and after
attachment, the TAM was manually removed from the capsule, leaving behind only the
TAM and drug delivery hypodermic needle. This device was attached via catheters to a
200 μL osmotic pump as shown in Figure 28.
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Figure 27. TAM/Drug delivery needle and the capsule chamber for tissue aspiration

Figure 28. Capsule chamber/TAM/drug delivery needles connected to a 200 ul osmotic
pump via catheters. Note: The device is attached to the vacuum system.
The 200 μL osmotic pumps were purchased from ALZET and were primed
according to the manufacturer’s procedure [66]. This was done to ensure osmotic
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pumping would begin as soon as the pump was placed into the intestine after the
TAM/drug delivery needle was attached.
During the study, we switched from a 7-day delivery pump to a 1-day delivery
pump due to shorter than expected attachment times (results shown later in the chapter).
By switching to the 1-day pump, the osmotic pump would ideally have had enough time
to deliver all its volume into the intestine before TAM detachment.
Experimental Design
•
•
•
•
•
•
•
•
•
•

Animal model: Yorkshire-domestic cross
Animal size: 20-35 kg (8-10 weeks old)
Dose delivered: 20 mg adalimumab
Volume delivered via osmotic pump: 200 μL
Sample: serum
Number of animals: 6 animals
Study duration: 14 days (7 delivery + 7 pharmacokinetics) or 7 days after device
detaches
Sampling frequency: 0, 6, 12, 24 hours and then once daily to necropsy
Gross pathology
Histopathology of the site (H&E)

Experimental Groups
1) Negative control (n=1): This pig had drug injected into the lumen of the small
intestine via an osmotic pump for 7 days. There was no TAM/drug delivery needle in this
animal, only an osmotic pump.
2) Positive control (n=1): This pig had drug fully injected into the submucosa of
the small intestine manually with a needle and syringe.
3) Experimental groups (n=4): These pigs received injections into the submucosa
of the small intestine using the drug delivery device with an osmotic pump sutured
downstream of the intestine. The drug was injected after the tissue was aspirated into a
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special "tissue capture mechanism" (TAM). In this study, the experimental groups were
separated into:
a.

(n=2) 7-day drug delivery osmotic pumps

b.

(n=2) 1-day drug delivery osmotic pumps

Surgery/Experimental Procedure
Step 1. Weigh the animal, record weight (in lbs and kg).
Step 2. Administer the anesthetics (TKX shot) and atropine (to decrease salivation).
Step 3. Place the animal on the surgery table. Trim the hair over the abdomen of the pig
and clean the skin with isopropyl alcohol and povidone-iodine to create a sterile field.
Step 4. Once the pig is anesthetized, place a jugular catheter for blood samples.
Step 5. Collect 1ml of jugular venous blood samples into an EDTA blood collection tube
before capsule deployment. (t=0)
Step 6. Cut the skin of the abdomen using scissors for several centimeters over the region
of the intestinal tissue.
Step 7. Bring and secure the desired intestinal tissue (duodenum, jejunum, or ileum) up
into the incision field.
Step 8. Cut open the intestine a few centimeters to gain access into the small intestine
lumen.
Step 9. Suture osmotic pump within the intestinal lumen. The osmotic pump is to be
connected to the capsule device via a 15 cm catheter.
Step 10. Once the osmotic pump is sutured in place (step 9 and step 10 can be reversed),
place capsule inside the lumen of the intestine and aspirate tissue to allow for attachment.
a. Place the device against the intestinal tissue and feels for intimate contact.
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b. With no air pockets surrounding the device, open the vacuum valve. This will cause
intestinal tissue to aspirate into the device (Figure 29).
c. The attachment needles will now be attached to the intestinal tissue (through
the submucosa but stopping before puncturing the serosa) Note: This was proven in
previous experiments.
d. Remove the device from the vacuum system (Figure 30).
e. Over the next few days, the submucosa will die and slough off causing the
device to naturally be released from the tissue.
Step 11. Check for strong attachment by giving a slight tug on the capsule. Make note if
it does not attach but continue to attempt attachment up to 5 times.
Step 12. Once the capsule has successfully attached to the small intestine, seal the
injection site with skin glue/sutures to prevent leakage of the intestinal fluid into the
peritoneal cavity. Suture marker beads next to the attachment site to allow reference for
X-ray (Figure 31).
Step 13. Close the skin of the pig using sutures in a running fashion.
Step 14. Give the animal a subcutaneous injection of buprenorphine (0.05 mg/kg) for
analgesia.
Step 15. Remove the swine from anesthesia and place it into a clean, warm area for
recovery.
Step 16. Using the indwelling jugular catheter, collect 1 ml of jugular venous samples
into EDTA blood collection tubes at the following time points post capsule deployment.
(t= 6, 12, 24 hours, and once daily to necropsy).
Step 17. After 1 day, allow the pig to return to normal eating habits.
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Step 18. Continue collecting blood samples up until necropsy on day 14, or once the
device detaches collect blood for 7 days after.
Step 19. On day 14, if the animal is still alive, euthanize it using Fatal-Plus. Collect
tissues for histology if desired.
Step 20. Send blood samples to a laboratory for analysis.

Blood Collection:
•
•
•
•
•

Blood Sample Site/Volume: Jugular vein or other accessible veins, ~2 mL
Type of Blood Tubes: K2EDTA
Type of Sample: Plasma (~400 µL)
Sample Storage and Shipment: -60 to -80°C
Each blood sample is collected from the pig jugular vein, or another suitable
vessel via direct venipuncture, placed into a chilled tube containing K2EDTA as
the anticoagulant, and inverted several times to mix. Blood samples are kept on
wet ice until centrifugation.

Plasma Preparation and Storage:
Blood samples were centrifuged at a temperature of 4°C, at 3,000 x g, for 5
minutes. All samples were maintained chilled throughout processing. Plasma was
collected into pre-labeled polypropylene tubes and placed in a freezer at -60 to -80°C
until delivered to PBL Assay Science for analysis. The assay work is described in the in
vivo study 2 section.
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Figure 29. Tissue aspirated into TAM/drug delivery needle

Figure 30 Tissue still aspirated after TAM/drug delivery needle has been removed from
the aspiration system
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Figure 31. Sutured marker beads for reference of TAM/drug delivery needle during
radiographs

Animal Housekeeping Information
Radiographs: The animals were X-rayed at t= 0, 6, 12, 24 hours, and once daily
until the device was determined to be detached. The device was considered detached by
using the marker beads as a relative position of the device. Radiographs were not taken
over the weekends. The radiographs were taken from either lateral side of the animal.
These were attempted without snaring of the animal but sometimes snaring was required.
Occasionally the hind leg was superimposed on a radiograph. To counter this, the hind
leg was pulled back by a technician, while the other took the radiograph.
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Blood Draws: Blood draws were taken at the same time points as the radiographs but
continued seven days after the device detached because the half-life of adalimumab is
seven days. Blood draws were not taken on the weekends, hence the gap in data in the
results section. The blood draws in this study were taken from the indwelling jugular vein
by one staff member, while another snared the animal. The catheter was first flushed with
heparinized saline, the blood was then drawn, and lastly, the catheter was flushed again.
Medications: Meloxicam was administered every 24 hours for 2-5 days postprocedure.
2.7.5

Results

TAM/Drug Delivery Needle Attachment and Pump Duration
As described in the design, the TAM and drug delivery needle were integrated into a
single device, so they attached and detached together. The osmotic pump was sutured
downstream of the device. In commercial versions of the device, the pump will be
integrated into the TAM. The device attachment times were determined via X-rays. By
using the marker beads as a reference, the device's attachment/detachment status could be
determined. The results of the attachment of this study are shown here (Table 4):
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Table 4. Attachment duration of drug delivery TAM and osmotic pump in study 1.
Pig ID

Description

TAM
Attachment
Duration

Pump Attachment
Duration

Exp 1: 7-Day

7 Day Pump/TAM

52 - 100 hours
(~2.2 - 4.2 days)

52 - 100 hours
(~2.2 - 4.2 days)

Exp 2: 7-Day

7 Day Pump/TAM

24-52 hours
(~1-2.2 days)

Neg 1

Pump Only- Negative Control

NA

24-52 hours
(~1-2.2 days)
52- 75 hours
(~2.2-3.2 days)

Pos 1

Direct Syringe InjectionPositive Control

NA

NA

Exp 3: 1-Day

1 Day Pump/TAM

Exp 4: 1-Day

1 Day Pump/TAM

53-76 hours
(~2.2-3.2 days)
53-76 hours
(~2.2-3.2 days)

53-76 hours
(~2.2-3.2 days)
53-76 hours
(~2.2-3.2 days)

Since the facilities are shut down on weekends and X-rays are only taken once a
day, the attachment time is shown as a range of time. The early time is the last known
time of attachment (Figure 32) and the later time is the next time checked that showed
certain detachment (Figure 33). All devices were attached to the distal ileum.

Figure 32. A representative x-ray of an attached TAM/Drug delivery needle. The yellow
square outlines the osmotic pump and the red circle outlines the TAM/Drug delivery
needle. Between the two are the marker beads.
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Figure 33. A representative x-ray of a detached TAM. Only the marker beads are shown
in the x-ray.
Drug Delivery
The plasma concentration levels for the six different animals are shown below (Figure
34).
in vivo Study 1 Plasma esults
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Figure 34. Adalimumab plasma concentration levels from in vivo study 1. Exp 1, Exp 2,
Exp 3, and Exp 4 used the TAM/Drug delivery needle and either a 7-day osmotic pump
or a 1-day osmotic pump. Pos 1 used a direct needle injection using a manual syringe
pump (No TAM/Drug delivery device). Neg 1 used only an osmotic pump sutured into
the intestinal lumen.
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2.7.6

Complications/Conclusions
This work enabled the veterinarian, staff, and members of the Terry Research Lab

(TRL) to refine the procedures and analysis of the drug delivery experiments.
Due to attachment times being shorter than expected, 1-day osmotic pumps were
used for the last two animals. Another problem was that the pumps detached from the
suture, so a later experiment was performed with a new suturing method and this pump
remained intact for at least five days (directly before holiday shutdown so the pig had to
be euthanized after five days). This new suture method is explained in more detail in the
second study.
Regarding TAM attachment times, all but one TAM was successful in attaching
for at least two days. During this study, work was being done to optimize the TAM
attachment time for longer durations. As noted in the x-ray results, the osmotic pump
detached from the sutures, but a new method has been tested that improves pump
attachment times to exceed the TAM attachment time (used in vivo Experiment 2).
The concentration of adalimumab in systemic blood had mixed results. The
positive control showed relatively high levels of the drug in the blood, which
demonstrates that adalimumab can be delivered in the submucosa of the small intestine
and systemically thereafter via a hypodermic needle. Neg 1 showed higher drug
concentration in the blood than Exp 1 and Exp 2 (7-day pumps) and Exp 4 (1-day pump)
but had similar results to Exp 3 (1-day pump). The results of the negative control were
puzzling. Adalimumab may be absorbed across a mucosal surface to some degree, which
is a reason for the second in vivo experiment. Exp 3 (1-day pump) showed drug in the
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blood but was at least 10 times less concentrated than the positive control and similar in
concentration to the negative control. This was a methods development study, so the
number of pigs in the results did not meet the power for statistical significance.
We identified several possible reasons for poor drug delivery from the
experimental groups and explored them in the next trial. These were:
1.

The osmotic function does not perform as anticipated in the small bowel.

2.

The drug injection needle possibly does not penetrate deeply enough.

3.

The TAM and/or osmotic pump possibly detaches early.

4.

Catheter possibly disconnects from the injection needle.

2.8 In vivo Experiment 2
2.8.1

Introduction

Improvements were made to address the above problems and potential problems and
the experiment was repeated. Before running the experiment, testing on pig carcasses was
performed to further optimize attachment and drug delivery. Many portions of the in vivo
experiment 2 were the same as the previous study, so unless otherwise noted, assume the
same procedure.
2.8.2

Objectives

1) Penetrate small intestinal tissue with the drug injection needle without
gastrointestinal perforation
2) Deliver drug systemically via the submucosa of the small intestine for at least one
day. This objective is different than the previous study in that we were looking for less
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time delivering drug and were more focused on proving any drug delivery, even over a
shorter period.
2.8.3

Hypothesis

The hypothesis for this study is the same as the previous study: The drug delivery
capsule will deliver non-absorbent biologics into the submucosa of the small intestine and
systemically thereafter. This was a methods development study, so the number of pigs
outlined in the procedure did not meet the power for statistical significance.
2.8.4

Materials and Methods

The perpendicular drug delivery device was used again for this experiment, with
slight modifications to make the profile smaller (Figure 35). The rigid arm of the drug
needle that attaches to the catheter was shortened. The overall catheter length from the
device to the osmotic pump was shortened to about five centimeters.

Figure 35. Smaller profile TAM and drug delivery needle device connected to a catheter.
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For this experiment, only 1-day 200 μL osmotic pumps were used for the
experimental groups. The 1-day pumps were used to ensure the best chance of systemic
drug delivery. Due to the osmotic pumps detaching early in the first study, they were
sutured differently in this study. This new suture method allowed the pump to attach to
the intestine for an extended period and not impact the TAM detachment. The method
required drilling a hole in the osmotic pump flow moderator cap to create an extra and
more secure anchoring point (Figure 36). This method was tested in animals and was
attached for at least five days, meaning the TAM would be the limiting factor since it
detaches before five days.

Figure 36. Osmotic pump with a hole drilled into the flow moderator cap.

Experimental Design
The experimental design was the same as the previous study with some
exceptions. The breed of pigs was changed to a Duroc Landrace cross breed because the
previous breed was unavailable. The duration for this study was shortened to about 36
hours for the inspection of the hardware and tissue in situ following delivery and to
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collect hardware and tissue. Due to the shorter study length, blood draws were taken
more frequently. Blood was drawn every six hours during the day. To accommodate the
more frequent blood draws, arterial catheters were implanted into the animals.
Experimental Groups
The animal groups for this study were:
1) Negative control (n=1): A 1-day delivery pump was used to directly deliver the
drug into the lumen of the intestine. Also, an osmotic pump with a long-coiled
catheter (~ 75 cm) was implanted to measure the function of the pump. This was
used to show how far the meniscus of the fluid had traveled, thus verifying
osmotic function (results in Chapter 3).
2) Positive controls (n=2): The TAM/Drug delivery needle was used in combination
with a syringe. The device was attached as normal, and then the drug was injected
manually with a syringe. This is different from the previous approach where only
a hypodermic needle and a syringe were used, and no TAM.
3) Experimental groups (n=3): These animals received injections into the submucosa
using the altered TAM shown in Figure 35. All devices were attached to a 1-day
osmotic pump sutured with the new method.
Surgery/Experimental Procedure
The procedure was the same as the previous study except for the following
alterations to these steps:
Step 9: Use the new suture method and the shorter catheter length.
Step 16: Blood collections are collected every six hours during the day.
Step 18 and 19: The study will only last 36 hours.
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Blood Collection
This time the studies were performed to avoid the weekends so that blood draws
were taken more often. The total number of blood draws was limited because of the
available funds for one Enzyme-linked immunosorbent assay (ELISA) kit. Each ELISA
kit contains 96 wells to tests for adalimumab plasma concentration, however several of
those wells are occupied for standards and each plasma sample was duplicated. Based on
this, 34 total blood draws were taken. Due to the limited number of blood draws, each
animal received five blood draws and the positive controls received an extra two blood
draws each.
Plasma Preparation and Storage
Same as the previous study
Animal Housekeeping Information
The same as the previous study, but with different duration of housing based on
the blood samples described in the blood collection paragraph.
2.8.5

Results

TAM/Drug Delivery Needle Attachment and Pump Duration
The results of the TAM and osmotic pump attachment times are shown in
Table 5.
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Table 5. Attachment duration of drug delivery TAM and osmotic pump in study 2.
Pig ID

Description

Neg 1

Negative Control

Exp 1

1-day osmotic pump

Exp 2

1-day osmotic pump

Exp 3

1-day osmotic pump

Pos 1

Positive Control

Pos 2

Positive Control

Duration until
Necropsy
34 hours
(~1.4 days)
33.5 hours
(~1.4 days)
31.25 hours
(~1.3 days)
30 hours
(~1.3 days)
48 hours
(~2 days)
46 hours
(~1.9 days)

TAM Attached
during
Necropsy?

Pump Attached
during
Necropsy?

N/A

YES

SLIGHTLY

YES

NO

YES

YES

YES

NO

N/A

NO

N/A

As shown in Table 5 all the devices and osmotic pumps were placed in the ileum
region of the small intestine. All six pigs were healthy and survived to the end of the
study. All four osmotic pumps placed into an animal stayed sutured in place for the entire
study (Figure 37). Out of the five animals that had a TAM attached to the small intestine
during surgery, one (Figure 38) still had the TAM strongly attached during necropsy,
while another had the TAM slightly attached. All the devices recovered were completely
intact. The TAM needles used for attachment were still UV glued to the TAM body, they
kept their appropriate needle angle (Figure 39), and the catheter connecting the drug
needle and osmotic pump was undamaged.
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Figure 37. An osmotic pump was sutured in place during necropsy.

Figure 38. A TAM with a drug delivery needle was still attached to the ileum during
necropsy.
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Figure 39. TAM needles were still in their 30-degree orientation.

Drug Delivery
The plasma results for the six different animals are shown below (Figure 40 and
Figure 41). The samples were run using two different standards. Figure 40 used kit
standard concentration samples of 0, 5, 10, 25, 50, 100 ng/mL while Figure 41 used a
more specialized dynamic range of standard samples called “adalimumab injection
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standards” and they included sample concentrations from 0, 0.0 2, 0.16, 0.8, , 20, 100
and 500 ng/mL (Appendix A).

Figure 40. Adalimumab concentration levels using the kit standard-based samples. Exp 1,
Exp 2, and Exp 3 used the TAM/Drug delivery needle and a 1-day osmotic pump. Pos 1
and Pos 2 used the TAM/Drug delivery device but instead of an osmotic pump, a manual
syringe pump was used to inject all 200 µL of drug into the intestinal wall. Neg 1 used
only an osmotic pump sutured into the intestinal lumen.
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Figure 41. Adalimumab concentration levels using the modified "adalimumab injection
standard" based samples. Exp 1, Exp 2, and Exp 3 used the TAM/Drug delivery needle
and a 1-day osmotic pump. Pos 1 and Pos 2 used the TAM/Drug delivery device but
instead of an osmotic pump, a manual syringe pump was used to inject all 200 µL of drug
into the intestinal wall. Neg 1 used only an osmotic pump sutured into the intestinal
lumen.

Overall, the two graphs had similar trends. Both positive groups showed relatively
high levels of adalimumab in the plasma, especially Pos 2. Exp 3 showed comparable
drug levels, suggesting successful systemic biological drug delivery. Neg 1 showed an
insignificant level of drug and Exp 1 and Exp 2 showed little to no drug delivery.
2.8.6

Discussion/Conclusions

Based on the plasma results and hardware finding during necropsy, it was evident that
this study performed better than the previous study. The plasma results from study 2
indicated successful drug delivery for both positive controls and one experimental
treatment while study 1 had no drug delivery for any group. By reducing the post
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treatment time for study 2, all the components were located easily. This made it easy to
inspect the hardware for any signs of failure. In the previous study, the radiographs were
used to determine if the TAM device or osmotic pump was still attached. The images
gave a general idea if the TAM or osmotic pump was still attached or at least in the
general area. However, this method was difficult to confidently say the device was still
attached. Since this study was shorter than the previous, the device and pump were
checked for attachment during necropsy. The duration until necropsy varied slightly per
animal because of different initial surgery times and the amount of blood draws available
to use in the ELISA kit was limited. Overall, the hardware stayed intact throughout the
whole study, meaning the catheter disconnecting from the injection needle was
eliminated as one of the identified possible reasons for poor drug delivery in study 1.
Generally, the plasma samples are diluted at 1:100, but based on the previous study, it
turned out most of the samples were falling below the lower limit of quantification
(LLOQ). Therefore, samples were run in a more concentrated form (1:50). Also, there
was a possibility that some of the samples would fall above the assay upper limit of
quantification (ULOQ) of kit standard and a more concentrated standard would allow one
to measure these samples. To avoid being below the LLOQ and above the ULOQ, the
assay was run with the additional “adalimumab injection standard.”
To find the drug concentration levels in the plasma, the optical densities (O.D) of the
standards were taken and two 4-parameter log fit standard curves were created. The
formulas were designed to get the standard curves only. The curve fit formula was not
used to get the sample concentrations directly, but a program called Softmax fitted the
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samples’ O.D. values to get their respective concentrations. Concentrations obtained
from the back-interpolation were multiplied by their respective dilution factors to get the
final analyte concentration per sample. The raw O.D. values are found in appendix A.
Although the two graphs showed a similar trend for most groups, Pos 2 had an
unexplainable difference between the 10-hour and 22-hour timepoints. Figure 41 shows a
more drastic increase in concentration compared to Figure 40. Also, the last two
timepoints for Pos 2 and the last time point for Pos 1 were above the ULOQ, therefore the
software could not calculate their actual concentrations. Similarly, the first time point of
Exp 1 was lower than the LLOQ. Each in vivo study was performed without statistical
power to draw conclusions, but there is evidence that suggests further progress is merited.
Although the drug delivery device showed successful delivery of a biological drug
in the small intestine, it used a relatively large commercially manufactured osmotic
pump. To fit an osmotic pump into the final capsule design, a theoretical custom osmotic
pump was designed.

Chapter 3: Osmotic Pump
3.1 Introduction
One of the most important aspects of drug delivery, besides the drug itself, is the
correct dosage. Underdosing gives poor therapeutic activity, and overdosing can cause
adverse events [67], [68]. Rate-controlled release systems allow maintaining the drug
concentration within the body at an optimum level [69], [70]. One of the most successful

58
release systems in recent years is the osmotic pump [71]. Osmotic micropumps require no
electrical energy, thus enabling drug delivery systems of the smallest size[72]. For these
reasons, an osmotic pump was chosen for drug delivery. One of the only commercially
available loadable osmotic pumps today is produced by ALZET and is the model for the
theoretical custom osmotic pump.

3.2 Theory of Osmotic Pumps
Osmosis is one of the most fundamental phenomena in biology, allowing cells to
balance solute concentrations [73], [74]. Osmosis occurs when two solutions contain
different concentrations of solutes and are separated by a selectively permeable
membrane [75], [76]. Solvent molecules travel along a gradient from low concentration
to high concentration, if the membrane allows [77]. The transfer of molecules continues
until equilibrium in concentration occurs [78]. If the membrane is semi-permeable, only
certain molecules can pass, usually the water molecules [79]. In the case of an osmotic
pump, water flows through the semi-permeable membrane, but the solute (osmotic agent)
is unable to pass through the semi-permeable membrane [80]. Consequently, it results in
a hydrostatic pressure difference across the membrane [81]. Osmotic pumps utilize this
hydrostatic pressure to “push” out the drug from the other end of the pump capsule [82].
There are three primary components to an osmotic pump: osmotic agent, solvent,
and the drug [72]. In our case, the solvent is the water molecules from the intestinal
chyme, mucous, etc. The drug that is loaded into the osmotic pump could ideally be any
drug with a reasonable viscosity. ALZET claims their pumps can deliver any viscosity up
to ketchup (~50,000 cps).[83] This means we are left with the osmotic agent used to
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“drive” the osmosis. To calculate the osmotic pressure, the van’t Hoff equation (2) is
used [84].
𝝅 = 𝒊𝑪𝑹𝑻

(2)

This equation shows the osmotic pressure (𝜋) of a solution is proportional to the
solute concentration (osmotic agent) and temperature, where C stands for the
corresponding osmotic agent solute concentration (mol/L), R is the molar gas constant
(8314 J mol− 1 K− 1), and T the absolute temperature (K). The van't Hoff factor i
represents the number of moles of solute dissolved in a solution per mole of added solid
solute (this value is 1 if a solute does not dissociate). When the osmotic pressure is
known, one can calculate the flow rate of a fluid using equation (3) [85].
𝑱 = 𝑲 × 𝑨 × (𝝈∆𝝅 − ∆𝑷)

(3)

where J is the volume transported per unit time, K is the permeability of the membrane, A
is the effective surface area of the membrane, 𝜎 is the osmotic reflection coefficient of the
membrane, ∆𝜋 is the difference in osmotic pressure, and ∆𝑃 is the difference in
hydrostatic pressure. Figure 42 shows the components of a simple osmotic pump [85].

Figure 42. Schematic of an osmotic pump.
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Knowing the components and the theory of an osmotic pump, we can now take a
closer look at ALZET’s osmotic pump (Figure 43.) They have three different sizes of
pumps, a 100 μL, 200 μL, and 2 mL reservoir. Each of these pumps has several different
release times ranging from one day to four weeks. Our goal was to deliver a drug for 4-7
days, so these pumps were an excellent product to model. However, we had a very strict
size constraint and all three of these models were too large. Consequently, we needed to
design a pump that would be compatible with our TAM design.

Figure 43. ALZET Osmotic Pump.
Our theoretical pump would use the same components that the ALZET pump
uses, just with different shapes and sizes. First, their pump uses sodium chloride as an
osmotic agent, so that would be used in our theoretical pump. The osmotic pressure
created from sodium chloride at body temperature is over 270,000 mmHg [71]. For our
system, the drug injection needle was around a total of 6 mm long with an inner diameter
of 0.159 mm (30 gauge) and two 90-degree elbows. Using these dimensions and a
velocity of 1 μL day to calculate the pressure loss in the system, the total loss would be
negligible, nearly 0. The pressure within capillaries is only around 20 mmHg [86],
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meaning the pressure generated from the pump would certainly overcome any pressure
loss from the tubing and needle bends and therefore would pump drug into the
bloodstream.
ALZET uses a cellulose ester blend as a semi-permeable membrane. They do not
specify exactly the contents of the blend due to intellectual property, but there is much
literature about different cellulose ester blends including cellulose acetate, cellulose
diacetate, cellulose triacetate, cellulose propionate, cellulose acetate butyrate, and
cellulose ethers [71]. We anticipate our custom pump would use one of the blends.
ALZET’s design is different than the simple schematic in Figure 43 in that their
movable portion does not push from one direction, but rather radially contracts to push
the drug out. The movable portion is a thermoplastic hydrocarbon elastomer. Some
designs use a piston to push the drug out (Figure 44) [87]. We used this piston-driven
device for our theoretical pump.

Figure 44. Example of a piston-driven osmotic pump.

3.3 Functional Requirements of Osmotic Pump
1. Component Materials and Properties
The osmotic pump used in the final will be designed with non-toxic parts and the osmotic
pump used in experiments will be a commercially available osmotic pump.
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2. Drug Chemistry, Manufacturing, and Controls (CMC)
Parts or materials of the TAM in contact with the drug shall be stable. A limited drug
shelf life shall not limit the TAM shelf life, and vice versa.
3. Drug Loading
The TAM should contain a feature that allows the loading of a drug before going in-vivo.
4. Manufacturability
The system shall be manufacturable in a timely fashion on a scale of 100,000 units/year.
Note: this quantity is different from the cost quantity to make a conservative case in both
categories.
5. Drug Payload Description
The theoretical osmotic pump should work for the following payloads.
Table 6. Function requirement for drug delivery payload.
Payload Type Target Concentration Delivery Rate Duration Total Volume
GLP-1
10 μg μL
10 μg day
4-7 days
μL week

6. Drug Payload Material and Viscosity
The drug will be in a liquid format with viscosity and fluid properties based on the
commercially available formulation.

3.4 Design of Osmotic Pump
After each of the components has been selected, the shape and size of the osmotic
pump were modified to fit within the final capsule design. Based on ALZET’s
dimensions, the drug reservoir volume is at a minimum of 20% of the pump’s total
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volume. If the volume of the drug we are trying to deliver in a week is 7 µl, and we
follow ALZETs drug reservoir to pump volume ratio, our pump size would be about 35
mm3. As a safety factor, a 30% clearance was given in the design making the total pump
volume 45 mm3. To satisfy these conditions, a torus-shaped, piston-driven, osmotic pump
was designed (Figure 45).

Figure 45. Schematic of the torus-shaped osmotic pump
The volume of a torus is:
𝑽 = (𝝅𝒓𝟐 )(𝟐𝝅𝑹)

(4)

where R is the major radius and r is the minor radius. In our design, R is 4 mm and r is
0.75 mm resulting in a total pump volume of approximately 45 mm3. The thickness of the
outer shell is 0.15 mm. To insert the drug injection needle a small arc (30-degrees or
about 8% of the total volume) of the torus was removed (Figure 46), resulting in a final
pump volume of about 41 mm3. ALZET’s 100 μL pump has a semi-permeable membrane
thickness of 0.45 mm and an osmotic agent thickness of 0.30 mm. The regions that
contain the semi-permeable membrane, osmotic agent, and drug are illustrated in the halfsection view in Figure 47. In our design, the semi-permeable region was about 20-
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degrees of the pump, which is around 1 mm thick, with a radius of 0.6 mm. The osmotic
agent is filled between the semi-permeable layer and the piston. The amount of osmotic
agent required should be tested to determine the delivery rate and duration. The
biological drug fills the remaining volume from the piston to the hypodermic needle. The
30-gauge hypodermic needle consists of two 90-degree bends with a total length of
around 6 mm. Table 7 shows all the components, materials, and dimensions required to
construct the custom osmotic pump. ALZET’s 100 μL pumps are sold at around $24.00,
with a lowered assumed unit cost. The components, materials, and overall size of our
custom osmotic pump are similar to ALZET’s 100 μL pump, therefore we expect our unit
cost to be lower than $24.00. The file for the osmotic pump is found here:
https://unl.box.com/s/wxb06ud6dox4bw222rivbc3po5vaf0zb or Wankum_Ben\Capsule
Project\Final Device Files for Progenity\osmotic_Pump_file. A detailed drawing with
dimensions is shown in Figure 48 and the file is found here:
https://unl.box.com/s/u1yyhetpcx08ovdrmhkplle3mzwgyaar or Wankum_Ben\Capsule
Project\Final Device Files for Progenity\osmotic_Pump_file_drawing.
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Figure 46. CAD design of a torus-shaped osmotic pump with a drug injection needle.

Figure 47. Half-section view of the osmotic pump showing the spherical-shaped piston,
drug location, osmotic agent location, and semi-permeable membrane.
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Figure 48. Drawing of the osmotic pump. Units are in millimeters.
Table 7. List of components, materials, and dimensions for the torus-shaped osmotic
pump
Component

Material

30 gauge
Hypodermic
Needle

Dimension
~ 0.5 mm then 90-degree bend
towards the center, 3.5 mm then

Stainless Steel or PLA

Semi-Permeable
Membrane

Cellulose Ester Blend

Osmotic Agent

Sodium Chloride

90-degree bend up, 0.75 mm to
the tip of the needle, 30 gauge =
ID of 0.159 mm
0.6 mm radius, 20-degrees
(~5%) of pump
Fill in the void between the semipermeable membrane and the
piston

Spherical-Shaped
Piston
Drug
Outershell

Stainless Steel or PLA

0.6 mm radius

Preference

N/A
R = 4 mm, r = 0.75 mm, and
0.15 mm wall thickness

Stainless Steel or PLA
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3.5 Function of Osmotic Pump in the Intestine
To our knowledge, there has been no proof of ALZET’s osmotic pumps being
used in any portion of the small or large intestine. To prove the feasibility of osmotic
drug delivery in the intestine, an ALZET 1-day, 200 μL osmotic pump was sutured into
the ileum. The osmotic pump was loaded with black India ink, primed in saline at 37o C
for 3 hours, and a 75 cm tube was attached. The meniscus of the ink was measured before
implantation (Figure 49). The pump and tubing were then sutured into a porcine intestine
via enterotomy. After surgery, the animal recovered and resumed its normal diet and
activity for over a day, until it was euthanized for inspection. The pump was found
sutured in place, the meniscus of India ink was measured (Figure 50), and the volume of
ink delivered was calculated. The total volume of ink delivered was approximately 220
μL, which was close to the e pected 200 μL for the lot we received. This e periment
strongly suggests that an osmotic pump can be used in the intestine for accurate drug
delivery.
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Figure 49. Pre-implantation of an osmotic pump with India ink meniscus.

Figure 50. Osmotic pump with India ink meniscus after being in a porcine intestine for
over 24 hours.
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Chapter 4: Discussion and Conclusions
The overall scientific goal of the research was to utilize subcutaneous needle
injection methodology used for parenteral systemic biologic drug delivery to solve the
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or
cancers. This was to be accomplished by demonstrating proof-of-feasibility of systemic
biological drug delivery via a needle injection into the submucosa of the small intestine.
This was completed by integrating the TAM with a commercial off-the-shelf (COTS)
drug delivery system. The COTS system used to deliver the drug in this work was
AZLET’s osmotic pumps. The pumps were connected to a hypodermic drug delivery
needle via a thin, tubed catheter. The drug delivery needle was developed to administer
the drug into the submucosa of the small intestine. The drug delivery needle was
designed and integrated into the TAM body and tested on the benchtop. The final design
of the drug delivery needle was a needle that perpendicularly pierced the intestinal tissue
upon actuation of the attachment sequence.
After the delivery needle consistently and successfully performed on excised
swine tissue, it was tested in live pigs. Two separate tests were performed on six animals
each. The goal of the studies was to deliver a biological drug (adalimumab) with the
TAM and drug delivery needle via an osmotic pump. Positive and negative controls were
used for comparisons. The first study did not go as planned, since the TAM was
detaching sooner than expected, but the experimental procedure was learned and there
were still questions to be answered, so the experiment was repeated with modifications.
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The second study showed much stronger evidence of drug delivery, with both positive
controls and an experimental group showing adalimumab in the plasma results. Both
studies were a methods development study, so the number of pigs in the results did not
meet the power for statistical significance.
The other goal of this project was to design a custom osmotic pump that could
theoretically be introduced into the full device. The theory of osmotic pumps was studied
and ALZET’s commercial osmotic pumps were used as a reference in the design of the
custom pump. A torus-shaped, piston-driven, osmotic pump was designed to fit within
the capsule. An ALZET osmotic pump was tested with India ink in the small intestine
and showed evidence of accurate drug delivery. Although there was no statistical power
in these experiments, the animal studies showed drug delivery, suggesting an osmotic
pump can be used for drug delivery, but a full-scale study with statistical power should be
performed.

4.1 Future Work
Drug delivery using injection into the intestinal submucosa with an ingestible
device is a radical approach for the administration of agents with poor oral
bioavailability. However, with this approach, the innovation potential is large.
Specifically, the ability to deliver unmodified drugs, which take years and billions of
dollars to develop. Although the drug delivery needle showed proof of feasibility to
systemically deliver drug via injection into the intestinal wall, there were drawbacks to
the study design. As stated, this study was a methods development study, so future
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studies should include additional animals to draw more conclusions. Numerous technical
and regulatory hurdles need to be negotiated before patient trials can be performed.
One of the main concerns of the capsule designs is how will a swallowed device
latch on strongly enough to the mucosal surface so that it can perform its complete task.
At the time of this writing, TRL is working on a coil spring system to provide intimate
contact with the intestinal wall. There are risks of full perforation, obstruction, and other
mechanical complications. These complications will occur but the key is to keep the
incidence very low during studies.
As discussed in the introduction of this work, bioavailability is a major
benchmark to determine the success of a device. A future study should include an animal
being administered adalimumab via IV. This would allow one to calculate the
bioavailability of the device by comparing the AUC of the device to the AUC of an IV
administration.
Since attachment times were shorter than expected, future work should be done
on optimizing TAM attachment time. Once a reliable long-term attachment is achieved, it
would be interesting to run another drug delivery test. In vivo study 1 was designed to
accomplish this and might be useful to rerun after attachment time is lengthened.
After my work was complete, the new injection needle and TAM were integrated
into the capsule system that was designed in another phase of the project (Figure 51). The
capsule system implemented all aspects of the final design, except for the custom osmotic
pump; a sham pump was used instead. The semi-complete capsule system should be
evaluated in vivo to test its ability to perform the full attachment and voiding sequence.
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Figure 51. The full concept of the capsule system.
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Appendices
Appendix A: Standard Curves and Raw Data from In Vivo Experiment 2
The following tables and figures were provided by PBL Assay Science:
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Table 8. Adalimumab kit standard curve used to measure adalimumab concentrations for
plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141
(Pos 1), and 163 (Pos 2). LLOQ (Conc.) = 5 ng/ml.
Standard

Conc.
(ng/ml)

Standard 1

100

Standard 2

50

Standard 3

25

Standard 4

10

Standard 5

5

Blank

0

O.D.
1.399
1.349
1.139
1.093
0.834
0.817
0.497
0.535
0.308
0.289
0.012
0.01

Mean O.D. Std. Dev.

CV%

Calculated
% Recovery
Conc.

1.374

0.035

2.6

100.409

100.409

1.116

0.033

2.9

49.963

99.926

0.826

0.012

1.5

24.52

98.082

0.516

0.027

5.2

10.595

105.953

0.299

0.013

4.5

4.7

93.996

0.011

0.001

12.9

0.011

NaN

Figure 52. 4-parameter log fit standard curve used to measure adalimumab concentrations
for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141
(Pos 1), and 163 (Pos 2).
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Table 9. Adalimumab ELISA: Group 136 (Neg 1). Measured adalimumab concentrations
of the samples from group 136 (Neg 1). Values below the LLOQ (5 ng/ml) are marked in
red.
Sample
136 A
136 B
136 C
136 D
136 E

O.D.
0.027
0.025
0.044
0.041
0.057
0.055
0.056
0.053
0.056
0.058

Mean O.D. Std. Dev.
0.026
0.001

CV%
5.4

Concentration Final Conc.
0.148
7.402

0.043

0.002

5

0.329

16.449

0.056

0.001

2.5

0.491

24.547

0.055

0.002

3.9

0.472

23.621

0.057

0.001

2.5

0.503

25.168

Table 10. Adalimumab ELISA: Group 137 (Exp 1). Measured adalimumab
concentrations of the samples from group 137 (Exp 1). Values below the LLOQ (5
ng/ml) are marked in red.
Sample
137 A
137 B
137 C
137 D
137 E

O.D.
0.012
0.01
0.202
0.179
0.714
0.669
0.646
0.648
0.747
0.723

Mean O.D. Std. Dev.
0.011
0.001

CV%
12.9

Concentration Final Conc.
0.011
0.553

0.191

0.016

8.5

2.546

127.319

0.692

0.032

4.6

17.432

871.582

0.647

0.001

0.2

15.474

773.702

0.735

0.017

2.3

19.521

976.047
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Table 11. Adalimumab ELISA: Group 139 (Exp 2). Measured adalimumab
concentrations of the samples from group 139 (Exp 2). Values below the LLOQ (5
ng/ml) are marked in red.
Sample
139 A
139 B
139 C
139 D
139 E

O.D.
0.419
0.395
0.149
0.152
0.421
0.396
0.412
0.371
0.364
0.363

Mean O.D. Std. Dev.
0.407
0.017

CV%
4.2

Concentration Final Conc.
7.35
367.48

0.151

0.002

1.4

1.861

93.056

0.409

0.018

4.3

7.39

369.502

0.392

0.029

7.4

6.938

346.91

0.364

0.001

0.2

6.224

311.19

Table 12. Adalimumab ELISA: Group 140 (Exp 3). Measured adalimumab
concentrations of the samples from group 140 (Exp 3). Values below the LLOQ (5
ng/ml) are marked in red and those above the ULOQ (100 ng/ml) are marked in green.
Sample
140 A
140 B
140 C
140 D
140 E

O.D.
0.718
0.714
0.097
0.089
1.499
1.499
1.372
1.506
1.293
1.497

Mean O.D. Std. Dev.
0.716
0.003

CV%
0.4

Concentration Final Conc.
18.586
929.286

0.093

0.006

6.1

0.983

49.137

1.499

0

0

151.412

7570.61

1.439

0.095

6.6

123.165

6158.244

1.395

0.144

10.3

107.061

5353.028
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Table 13. Adalimumab ELISA: Group 141 (Pos 1). Measured adalimumab concentrations
of the samples from group 141 (Pos 1). Values below the LLOQ (5 ng/ml) are marked in
red and those above the ULOQ (100 ng/ml) are marked in green.
Sample
141 A
141 B
141 C
141 D
141 E
141 F
141 G

O.D.
0.036
0.037
1.228
1.312
1.372
1.545
1.508
1.4
1.487
1.561
1.459
1.683
1.703
1.665

Mean O.D. Std. Dev.
0.037
0.001

CV%
1.9

Concentration Final Conc.
0.261
13.036

1.27

0.059

4.7

74.563

3728.156

1.459

0.122

8.4

131.429

6571.474

1.454

0.076

5.3

129.452

6472.613

1.524

0.052

3.4

166.098

8304.901

1.571

0.158

10.1

200.317

10015.83

1.684

0.027

1.6

350.093

17504.668

Table 14. Adalimumab ELISA: Group 163 (Pos 2). Measured adalimumab concentrations
of the samples from group 163 (Pos 2). Values below the LLOQ (5 ng/ml) are marked in
red and those above the ULOQ (100 ng/ml) are marked in green.
Sample
163 A
163 B
163 C
163 D
163 E
163 F
163 G

O.D.
0.088
0.095
1.524
1.587
1.558
1.568
1.513
1.677
1.567
1.62
1.668
1.618
1.663
1.694

Mean O.D. Std. Dev.
0.092
0.005

CV%
5.4

Concentration Final Conc.
0.962
48.08

1.556

0.045

2.9

187.914

9395.716

1.563

0.007

0.5

193.761

9688.074

1.595

0.116

7.3

222.22

11110.981

1.594

0.037

2.4

220.742

11037.106

1.643

0.035

2.2

279.389

13969.457

1.679

0.022

1.3

338.978

16948.898
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Table 15. Additional adalimumab standard curve used to measure adalimumab
concentrations for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2),
140 (Exp 3), 141 (Pos 1), and 163 (Pos 2). LLOQ (Conc.) = 0.160 ng/ml.
Standard

Conc.
(ng/ml)

Standard 1

500

Standard 2

100

Standard 3

20

Standard 4

4

Standard 5

0.8

Standard 6

0.16

Standard 7

0.032

Blank

0

O.D.

Mean O.D.

Std. Dev.

CV%

Calculated
Conc.

% Recovery

1.766
1.343
1.595
1.253
0.921
0.755
0.339
0.278
0.081
0.08
0.025
0.022
0.011
0.011
0.009
0.008

1.555

0.299

19.2

362.648

72.53

1.424

0.242

17

118.166

118.166

0.838

0.117

14

18.866

94.331

0.309

0.043

14

4.294

107.352

0.081

0.001

0.9

0.885

110.577

0.024

0.002

9

0.131

81.956

0.011

0

0

NaN

NaN

0.009

0.001

8.3

NaN

NaN
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Figure 53. 4-parameter log fit standard curve used to measure adalimumab concentrations
for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141
(Pos 1), and 163 (Pos 2).

Table 16. Adalimumab ELISA: Group 136 (Neg 1). Measured adalimumab
concentrations of the samples from group 136 (Neg 1). Values below the LLOQ (0.160
ng/ml) are marked in red.
Sample
136 A
136 B
136 C
136 D
136 E

O.D.
0.027
0.025
0.044
0.041
0.057
0.055
0.056
0.053
0.056
0.058

Mean O.D. Std. Dev.
0.026
0.001

CV%
5.4

Concentration Final Conc.
0.165
8.234

0.043

0.002

5

0.383

19.15

0.056

0.001

2.5

0.561

28.028

0.055

0.002

3.9

0.541

27.041

0.057

0.001

2.5

0.574

28.686
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Table 17. Adalimumab ELISA: Group 137 (Exp 1). Measured adalimumab
concentrations of the samples from group 137 (Exp 1). Values below the LLOQ (0.160
ng/ml) are marked in red.
Sample
137 A
137 B
137 C
137 D
137 E

O.D.
0.012
0.01
0.202
0.179
0.714
0.669
0.646
0.648
0.747

Mean O.D. Std. Dev.
0.011
0.001

CV%
12.9

Concentration Final Conc.
NaN
NaN

0.191

0.016

8.5

2.421

121.058

0.692

0.032

4.6

13.272

663.613

0.647

0.001

0.2

11.892

594.579

0.735

0.017

2.3

14.749

737.443

Table 18. Adalimumab ELISA: Group 139 (Exp 2). Measured adalimumab
concentrations of the samples from group 139 (Exp 2). Values below the LLOQ (0.160
ng/ml) are marked in red.
Sample
139 A
139 B
139 C
139 D
139 E

O.D.
0.419
0.395
0.149
0.152
0.421
0.396
0.412
0.371
0.364
0.363

Mean O.D. Std. Dev.
0.407
0.017

CV%
4.2

Concentration Final Conc.
6.1
305.018

0.151

0.002

1.4

1.843

92.162

0.409

0.018

4.3

6.13

306.496

0.392

0.029

7.4

5.799

289.941

0.364

0.001

0.2

5.271

263.561
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Table 19. Adalimumab ELISA: Group 140 (Exp 3). Measured adalimumab
concentrations of the samples from group 140 (Exp 3). Values below the LLOQ (0.160
ng/ml) are marked in red.
Sample
140 A
140 B
140 C
140 D
140 E

O.D.
0.718
0.714
0.097
0.089
1.499
1.499
1.372
1.506
1.293
1.497

Mean O.D. Std. Dev.
0.716
0.003

CV%
0.4

Concentration Final Conc.
14.087
704.365

0.093

0.006

6.1

1.052

52.587

1.499

0

0

196.28

9813.987

1.439

0.095

6.6

128.757

6437.836

1.395

0.144

10.3

101.585

5079.237

Table 20. Adalimumab ELISA: Group 141 (Pos 1). Measured adalimumab concentrations
of the samples from group 141 (Pos 1). Values below the LLOQ (0.160 ng/ml) are
marked in red.
Sample O.D.
141 A
0.036
0.037
141 B
1.228
1.312
141 C
1.372
1.545
141 D
1.508
1.4
141 E
1.487
1.561
141 F
1.459
1.683
141 G
1.703
1.665

Mean O.D. Std. Dev. CV%
0.037
0.001
1.9

Concentration Final Conc.
0.304
15.198

1.27

0.059

4.7

60.883

3044.143

1.459

0.122

8.4

145.365

7268.227

1.454

0.076

5.3

141.197

7059.838

1.524

0.052

3.4

248.241

12412.032

1.571

0.158

10.1

480.591

24029.547

1.684

0.027

1.6

NaN

NaN
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Table 21. Adalimumab ELISA: Group 163 (Pos 2). Measured adalimumab concentrations
of the samples from group 163 (Pos 2). Values above the ULOQ (500 ng/ml) are marked
in green.
Sample
163 A
163 B
163 C
163 D
163 E
163 F
163 G

O.D.
0.088
0.095
1.524
1.587
1.558
1.568
1.513
1.677
1.567
1.62
1.668
1.618
1.663
1.694

Mean O.D. Std. Dev.
0.092
0.005

CV%
5.4

Concentration Final Conc.
1.032
51.58

1.556

0.045

2.9

368.148

18407.405

1.563

0.007

0.5

415.26

20763.02

1.595

0.116

7.3

906.42

45320.985

1.594

0.037

2.4

858.859

42942.952

1.643

0.035

2.2

NaN

NaN

1.679

0.022

1.3

NaN

NaN

Appendix B: Drug delivery TAM fabrication process
Following are the materials, files, and instructions for building the drug delivery TAM:
Bill of Materials for Device
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Table 22. List of parts and suppliers.
Description
30 Gauge, ½ inch hypodermic needle
Laser-cut TAM needle 316 Full Hard
Stainless, .008" thickness

Supplier
Global Medical Products (#48-2015)
Micron Laser, Hillsboro, OR

Small Catheter- Medical grade micro
vinyl catheter tubing (I.D. x O.D.:
0.02 ″ 0.0 5″ 0.69mm 1.1 mm

Scientific Commodities Inc. (SCI)
(cat.# bb 1 85 v a 50′ roll

Large- Catheter- Medical grade micro
vinyl catheter tubing (I.D. x O.D.:
0.011″ 0.025″ 0.28mm 0.6 mm

Scientific Commodities Inc. (SCI)
(cat.# bb 1 85 v 1 50′ roll

200 μL 1 day delivery osmotic pump
(other pumps from ALZET may be
used depending on the volume and
duration of the study).
PGN-001 (adalimumab)

Alzet Osmotic Pumps- 2001D
Progenity

List of Files for Device
All files for the fabrication of the drug delivery TAM are found here:
https://unl.box.com/s/h6evar1gy8prq3eha0vvu18xgptvicxj
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Table 23. List of files with descriptions used to build the TAM.
File
TAM_with_sham_osmotic_pump_wgroove_perp
indicular_needleV3
https://unl.box.com/s/x4r9dbslauuft5hmzdbagfpd
5j1e6n80
6.5 mm 90-degree bend .2 mm bend radius
https://unl.box.com/s/d6tzdkgwk1rg11dch0nkus6
mllbdtau6
2mm 90-degree bend .2 mm bend radius
https://unl.box.com/s/b1f52e8kmsy7foq5r7c2entr
nvaevb9y
6mmdia_30d_bend_die
https://unl.box.com/s/v87def8nmay28m5a3ij5bq2
ghsvr0rvb
6mmdia_30d_bend_punch
https://unl.box.com/s/emrfk0s1v72sdgl62rs4otj9
5j76eufj

Description
Inventor model - TAM device
with hole for drug delivery
hypodermic needle
Inventor model- 6.5mm length,
90-degree bend, 0.2mm bend
radius mold
Inventor model- 2 mm length,
90-degree bend, 0.2mm bend
radius mold
Inventor model- 6 mm
diameter, 30-degree die
Inventor model- 6 mm
diameter, 30-degree punch

List of Tools and Supplies for Device
Table 24. List of tools and supplies for the TAM.
Tool/Supplies
UV glue
UV light
Microscope
VeroClear (StratasysOBJ-03271)
RGD450 (StratasysOBJ- 03308)

Description
Hold together TAM
needles and drug delivery
needle to TAM device
Cure UV glue
Confirm bend angles for
TAM needles and drug
delivery needle
3D print material for TAM
device
3D print material for
hypodermic needle and
TAM needle bending
molds
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Assembly Procedure
Step 1.
a.
b.
c.
d.

3D print the following files with their specified material:
TAM (VeroClear)https://unl.box.com/s/x4r9dbslauuft5hmzdbagfpd5j1e6n80
6.5 mm bending mold (RGD450)https://unl.box.com/s/d6tzdkgwk1rg11dch0nkus6mllbdtau6
2.0 mm bending mold (RGD450)https://unl.box.com/s/b1f52e8kmsy7foq5r7c2entrnvaevb9y
30-degree TAM needle bending mold punch and diehttps://unl.box.com/s/v87def8nmay28m5a3ij5bq2ghsvr0rvb
https://unl.box.com/s/emrfk0s1v72sdgl62rs4otj95j76eufj

Bending TAM needle
Step 2.
Remove the TAM needle from the laser cut sheet (Figure 54).
Step 3.
Place the non-bent TAM needle (Figure 55) onto the bottom 30-degree
TAM needle bending mold. (Figure 56).
Step 4.
Place the top 30-degree TAM needle bending mold over the TAM needle
and press down (Figure 57).
Step 5.
Separate the two molds and remove the bent TAM needles from the top
bending mold (Figure 58).
Step 6.
Take the 30-degree bent TAM needle (Figure 59) and confirm its angle
with a microscope.
Bending drug delivery needle
Step 7.
Bend the ½ inch 30-gauge hypodermic needle (Figure 60) 6.5 mm at 90degrees by using the 3D printed mold (Figure 61). Confirm the 90-degree bend
with a microscope (Figure 62).
Step 8.
Next, bend the hypodermic needle 90-degrees again with the 2 mm mold
(Figure 63). The needle should now have two 90-degree bends. Confirm the
angles with a microscope.
Step 9.
Snap off the yellow Luer lock from the hypodermic needle (Figure 64).
Assembling Device
Step 10. Place UV glue onto the bottom of the bent TAM needle and set it in the
slot on the TAM device. Cure the UV glue with a UV light (Figure 65).
Step 11. Slide the bent hypodermic needle into the TA device’s pre-existing hole
(Figure 65).
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Step 12. Cut 2 cm of the small catheter and place it over the hypodermic needle
arm.
Step 13. Bend down the hypodermic needle arm and catheter and fasten them to the
TAM device with UV glue (Figure 66).
Step 14. Insert the distal end of the small catheter into 2 cm of the large catheter.
Use UV glue to hold them in place (Figure 67).
Step 15. Lastly, attach the osmotic pump to the distal end of the large catheter.
Step 16. Fill and prime the osmotic pump according to ALZET’s guidelines:
https://www.alzet.com/guide-to-use/filling-priming-alzet-pumps/
Step 17. The device is then ready to be inserted into the intestine, attached, and to
deliver the drug according to the outline in “In vivo E periment 1” of this
document.

Figure 54. Laser-cut TAM needles.
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Figure 55. Non-bent TAM needle.

Figure 56. Non-bent TAM Needle in bottom 30-degree bending mold.
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Figure 57. TAM Needle in 30-degree bending molds.

Figure 58. Bent TAM Needle in top 30-degree bending mold.
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Figure 59. 30-degree TAM needle.

Figure 60. 1/2 inch 30-gauge hypodermic needle.
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Figure 61. Hypodermic needle in bending mold.

Figure 62. Hypodermic needle bent once.
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Figure 63. Hypodermic needle bent 90-degrees twice.

Figure 64. Hypodermic needle bent and snapped off from Luer lock.
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Figure 65. TAM with a drug injection needle (shorten arm used).
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Figure 66. Needle arm bent down and glued to a small catheter.

Figure 67. The final device without the osmotic pump.

